Skip to main content

Deloitte Dialogue powered by J&J

Sustainability of the pharmaceutical industry under the NHI

Under the NHI, governments’ focus is to maintain a cost-conscious drug procurement policy, so the primary focus will be on the essential medicines list, the price of medication, devices and services. In this scenario, what is the future for innovative pharmaceutical companies in South Africa and how does the industry support the NHI to enable more patients to have access to affordable medication, but also ensure the sustainability of the SA pharma sector?

On Friday, 6th May 2022, Deloitte Africa, in partnership with Johnson & Johnson, joined by representatives from Government, hosted a roundtable discussion to address the future of the industry. Deloitte Africa’s Life Sciences and Health Care Industry Leader/Chief Sustainability Officer, Ashleigh Theophanides, facilitated the conversation which comprised of the following guest panel:

  • Dr Mark Blecher: Chief Director, Health and Social Development, National Treasury
  • Rashmee Ragaven: Senior Manager, Invest SA, The Department of Trade, Industry and Competition (DTIC)
  • Aluwani Museisi: Senior Director, Government Affairs & Policy, Sub-Saharan Africa, Johnson & Johnson

Did you find this useful?

Thanks for your feedback

If you would like to help improve further, please complete a 3-minute survey